Comparative efficacy of prophylactic monoclonal (OKT3) and polyclonal antibodies (ATG) in immunologic high-risk renal transplant recipients.
Fukuuchi
F
F
Unit of transplantation, Hôpital Edouard Herriot, Lyon, France.
Lefrançois
N
N
Chapuis
F
F
Gebuhrer
L
L
Bosshard
S
S
Dubernard
J M
JM
Touraine
J L
JL
D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D001379:Azathioprine / Q000627:therapeutic use; D016009:Chi-Square Distribution; D016572:Cyclosporine / Q000627:therapeutic use; D003586:Cytomegalovirus Infections / Q000453:epidemiology; D006085:Graft Survival; D006801:Humans; D007114:Immunization; D007165:Immunosuppression Therapy / Q000379:methods*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000276:immunology* / Q000401:mortality; D008775:Methylprednisolone / Q000627:therapeutic use; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D011183:Postoperative Complications; D011239:Prednisolone / Q000627:therapeutic use; D012189:Retrospective Studies; D015996:Survival Rate; D013997:Time Factors
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D016572:Cyclosporine; D011239:Prednisolone; D001379:Azathioprine; D008775:Methylprednisolone